Study identifies miR-122 target sites in liver cancer, links 3 genes to patient survival
Columbus, Ohio – A new study of a molecule that regulates liver-cell metabolism and suppresses liver-cancer development shows that the molecule interacts with thousands of genes in liver cells, and that when levels of the molecule go down, which often happens during liver-cancer development, the activity of certain cancer-promoting genes goes up.
The findings could one day help doctors better predict survival in liver cancer patients and help determine whether the molecule — called microRNA-122 (miR-122) — should be developed as an anticancer drug. (The OSUCCC — James provides a primer on microRNA here.)
The study, reported in the journal Molecular Cell, was led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) and at Rockefeller University's Howard Hughes Medical Institute.
The researchers sought to biochemically (rather than computationally) define all miR-122 target sites in the liver and hepatocellular carcinoma (HCC), the most common form of liver cancer, and to learn which target genes were critical for liver cancer development or progression. miR-122 is found almost exclusively in liver cells, where its role includes regulating cholesterol and lipid metabolism.
The researchers identified more than 11,000 miR-122 binding sites in a mouse model. They further found that:
- miR-122 targets nearly 4,800 genes in humans;
- Of these targets, 965 are shared with mice;
- Of the shared targets, a majority are more highly expressed in HCC tumor tissue from patients;
- Loss of miR-122 in HCC results in the over-expression of certain cancer-related genes.
Increased levels of three conserved target genes, BCL9, SLC52A2 and STX6 in tumor tissues could predict poor survival of human HCC patients.
"Our goal is to understand how miR-122 regulates liver metabolism and suppresses cancer development, and to identify common targets in humans and mice that may be involved in HCC development," says co-principal investigator and OSUCCC — James researcher Kalpana Ghoshal, PhD, associate professor of pathology. "That knowledge is critical for determining whether this molecule should be developed as a possible therapeutic agent for liver cancer."
The findings significantly extend the number of miR-122 binding sites identified by earlier studies because the methods used by the investigators identified sites that other techniques miss, Ghoshal adds. (Note: one gene can have multiple microRNA target sites.)
For this study, Ghoshal and her colleagues used a mouse model that lacked miR-122, along with normal mice; liver cancer tissues and normal liver tissues from nine HCC patients; and data from 373 HCC patients in The Cancer Genome Atlas Liver Hepatocellular Carcinoma dataset.
Other key findings include:
Funding from the National Institutes of Health (grants CA193244, CA086978, NS034389, NS081706, NS097404, AI116943), a Pelotonia Idea Grant and a Pelotonia Fellowship supported this research.
Other researchers involved in this study were Juan M. Barajas (a pre-doctoral researcher in Ghoshal's lab who recently received a Howard Hughes Medical Institute Gilliam Fellowship for Advanced Study), Kun-yu Teng (doctoral trainee in Ghoshal's lab who received a Pelotonia Fellowship), The Ohio State University; Joseph M. Luna, Michael J. Moore and Robert B. Darnell, Howard Hughes Medical Institute, The Rockefeller University; Charles M. Rice, The Rockefeller University; Hui-Lung Sun, Howard Hughes Medical Institute, University of Chicago.
About the OSUCCC – James
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 49 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs sponsored by the NCI. As the cancer program's 308-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet designation, the highest honor an organization can receive for quality patient care and professional nursing practice. At 21 floors with more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care.
Amanda Harper, director, Media Relations
Direct: 614-685-5420; central media office: 614-293-3737
Related Journal Article